| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $79,825,215 ) (Continued on the next page) |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG074883 | PAPP-A as a Potential Target in Alzheimer's Disease | 000 | 2 | NIH | 11/7/2023 | $214,650 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK130854 | Role of SLCO3A1 in macrophage metabolite sensing and IBD | 000 | 2 | NIH | 12/14/2023 | $314,820 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166140 | Targeting Mineralocorticoid Receptor Condensates to Optimize Donor Heart Preservation | 001 | 2 | NIH | 1/12/2024 | $618,738 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160570 | Hydrogen Sulfide in Neonatal Airway Disease | 000 | 2 | NIH | 11/13/2023 | $536,787 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AR082134 | PHLPP inhibition and Osteoarthritis-Associated Pain | 000 | 2 | NIH | 12/7/2023 | $157,410 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03AI170571 | Role of PAPP-A in Graves' Ophthalmopathy | 000 | 2 | NIH | 12/1/2023 | $71,550 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K08DK134759 | Aging lymphocytes: senescence programs in lymphocytes relevant to human inflammatory bowel disease | 000 | 2 | NIH | 11/7/2023 | $163,590 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL151379 | Evaluating the natural evolution of myocardial stiffness in aging, sex differences, and through menopause transition in women, using a free-breathing magnetic resonance elastography approach | 000 | 2 | NIH | 12/25/2023 | $525,686 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA266999 | Genome-wide synthetic lethal screening for vulnerabilities in a cell model of succinate dehydrogenase-loss paraganglioma | 001 | 2 | NIH | 4/17/2024 | $9,290 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA266999 | Genome-wide synthetic lethal screening for vulnerabilities in a cell model of succinate dehydrogenase-loss paraganglioma | 000 | 2 | NIH | 11/22/2023 | $167,249 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 001 | 2 | NIH | 4/18/2024 | $26,975 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 000 | 2 | NIH | 12/29/2023 | $485,587 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB033008 | Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | 000 | 2 | NIH | 12/1/2023 | $576,204 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076636 | Advancing MR elastography to map mechanical signatures of key AD/ADRD processes | 000 | 2 | NIH | 11/7/2023 | $397,775 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS129549 | Development of an innovative in vivo voltammetric technique for measurements of tonic serotonin concentrations in the mammalian brain. | 000 | 2 | NIH | 11/30/2023 | $525,282 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DA056469 | Alaska Native Family-Based, Financial Incentives Intervention for Smoking Cessation: an RCT | 000 | 3 | NIH | 3/15/2024 | $559,854 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 001 | 2 | NIH | 4/18/2024 | $18,187 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 000 | 2 | NIH | 11/28/2023 | $327,341 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA265050 | New Therapuetics for Pancreatic Cancer | 000 | 3 | NIH | 4/12/2024 | $568,413 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG077706 | Project HoPe: Achieving Home Discharge for institutionally-bound Patients with PROMs, AI, and the EHR | 000 | 3 | NIH | 4/24/2024 | $1,099,388 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 000 | 3 | NIH | 3/21/2024 | $505,357 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL158548 | Novel Therapeutics for Cardiovascular Disease | 000 | 3 | NIH | 4/12/2024 | $617,264 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 002 | 3 | NIH | 4/17/2024 | $31,600 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 001 | 3 | NIH | 12/15/2023 | $568,795 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | T32AI170478 | Training Program in Immunology | 000 | 3 | NIH | 4/17/2024 | $315,294 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K24AG078179 | Temporal associations between systemic inflammation, cardiovascular risk profile and development of Alzheimer?s disease and related dementias in patients with rheumatoid arthritis | 000 | 3 | NIH | 4/19/2024 | $190,142 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA272257 | Translation of a novel combination therapy approach for non-Hodgkin lymphoma | 000 | 2 | NIH | 4/1/2024 | $70,432 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076515 | Defining the interactions of senescent immune cells and skeletal cells | 000 | 3 | NIH | 3/12/2024 | $428,154 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK139607 | Investigate the trafficking and function of polycystins in primary cilia and their implications for polycystic kidney disease | 000 | 1 | NIH | 4/1/2024 | $544,783 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01AI179609 | Mitochondrial Malfunction in T Cell Aging and Tissue Inflammation | 000 | 1 | NIH | 2/29/2024 | $581,040 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01AI179609 | Mitochondrial Malfunction in T Cell Aging and Tissue Inflammation | 001 | 1 | NIH | 3/4/2024 | $0 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA285345 | Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer | 000 | 1 | NIH | 3/15/2024 | $507,395 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 000 | 1 | NIH | 2/29/2024 | $571,063 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI178147 | Role of the CX3CL1-CX3CR1 signaling axis in IPMN | 000 | 1 | NIH | 3/1/2024 | $217,890 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG087361 | Investigating the Impact of Novel Senescent Microglia in Alzheimer's Disease Progression | 000 | 1 | NIH | 4/3/2024 | $461,058 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL169320 | Effects of Experimental Sleep Restriction in Offspring of Hypertensive Parents | 000 | 1 | NIH | 4/23/2024 | $720,956 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31HD112161 | Evaluating the mechanisms of cell free fetal DNA signaling in the promotion of labor | 000 | 1 | NIH | 2/28/2024 | $47,694 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 000 | 1 | NIH | 3/27/2024 | $226,364 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA286864 | Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer | 000 | 1 | NIH | 4/5/2024 | $452,180 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA286349 | Characterization and treatment of a novel model of radiation optic neuropathy using the tree shrew | 000 | 1 | NIH | 1/23/2024 | $226,364 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R13AR084329 | ORS Tendon Conference 2024: Mechanism to Therapy ? Emerging Technologies and Therapeutic Outcomes | 000 | 1 | NIH | 3/20/2024 | $15,000 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA282702 | Clonal growth and prediction of monoclonal B-cell lymphocytosis | 000 | 1 | NIH | 3/20/2024 | $245,120 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K08CA279652 | Elucidating the role of IRF4 in reprogramming the tumor microenvironment in follicular lymphoma | 000 | 1 | NIH | 1/10/2024 | $178,069 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K99HL171911 | The role of proteoglycans in Heparin-induced thrombocytopenia: Implications for pathophysiology, diagnosis and treatment | 000 | 1 | NIH | 1/11/2024 | $165,780 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK136208 | Inhibition of autoimmune diabetes by ST8Sia6 | 000 | 1 | NIH | 2/12/2024 | $454,682 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-?B Activation to Reverse Chronic Pulmonary Fibrosis | 000 | 1 | NIH | 4/18/2024 | $530,117 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA287495 | DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy | 001 | 1 | NIH | 1/26/2024 | $0 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA287495 | DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy | 000 | 1 | NIH | 1/26/2024 | $47,694 |
| 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01MH131623 | Uncovering the origin of hypermutability in adult brains | 000 | 1 | NIH | 11/15/2023 | $814,313 |
|